



PROVIDING ANSWERS FOR CANCER PATIENTS

Press release

February 5, 2025

Curasight announces an updated financial calendar 2025

Copenhagen, Denmark, 5 February 2025 - Curasight A/S (“Curasight” or the “Company” - TICKER: CURAS) announces that the Company’s Annual General Meeting will be held on 10 April 2025 and an updated financial calendar for rest of 2025

The Annual General Meeting of Curasight is planned to be held on 10 April 2025. Consequently, the financial calendar and information on the date of the Annual General Meeting set out in the Annual Report for the financial year 2024 are updated accordingly.

Curasight has thus scheduled the following dates for the remainder of 2025:

Deadline for submission of shareholder proposals to Annual General Meeting 2025

March 10, 2025

Annual General Meeting 2025

April 10, 2025

Annual Report 2024

February 27, 2025

Interim Report Q4 2024

February 27, 2025

Interim Report Q1 2025

May 29, 2025

Interim Report First Half 2025

August 28, 2025

Interim Report Q3 2025

November 27, 2025

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: uk@curasight.com

www.curasight.com

Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE[®]) and Radioligand Therapy (uTREAT[®]) Theranostic Platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.